How I treat higher-risk MDS
Blood · 01.05.2025 · 145 (18) · 2002-2011
DOI: 10.1182/blood.2024025271 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood, erschienen am 01.05.2025. Verfasst von Alain Mina und 1 weiteren Autor:innen. Beteiligte Einrichtung: Myeloid Malignancies Program, Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphological dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original International Prognostic Scoring System (IPSS) and revised IPSS have been used to risk-stratify patients with MDS to guide treatment strategies. In higher-risk MDS, the therapeutic approach is geared toward delaying leukemic transformation and prolonging survival. For more than a decade, the hypomethylating agents azacitidine and decitabine have been the standard of care and, when feasible, an allogeneic hematopoietic stem cell transplantation should be considered. However, the IPSS scoring systems solely rely on clinical, morphological, and cytogenetic features and do not account for somatic mutations present in >80% of cases. These genetic abnormalities have been shown to play a crucial role in prognostication, prompting the development of molecular IPSS, and the integration of genomic features into MDS classification systems in recent years. In this review, we delineate our approach to higher-risk MDS in the context of updated classifications and the latest prognostication tools. We use illustrative clinical cases to support our discussion and share insights from recent clinical trials, highlighting lessons learned.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Myeloid Malignancies Program, Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
ORCID-Profile: Rami Komrokji
Zitieren
APA
Mina, A., & Komrokji, R. (2025). How I treat higher-risk MDS. Blood, 145(18), 2002-2011. https://doi.org/10.1182/blood.2024025271
Vancouver
Mina A, Komrokji R. How I treat higher-risk MDS. Blood. 2025;145(18):2002-2011. doi:10.1182/blood.2024025271
BibTeX
@article{Mina2025,
author = {Mina, Alain and Komrokji, Rami},
title = {How I treat higher-risk MDS},
journal = {Blood},
year = {2025},
volume = {145},
number = {18},
pages = {2002--2011},
doi = {10.1182/blood.2024025271}
}
EUVIMED